Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

Journal of Clinical Oncology

Volumn 26, Issue 15, 2008, Pages 2512-2518

  Soussain, Carole ^a   Hoang Xuan, Khê ^b   Taillandier, Luc ^b   Fourme, Emmanuelle ^b   Choquet, Sylvain ^b   Witz, Francis ^b   Casasnovas, Olivier ^b   Dupriez, Brigitte ^b   Souleau, Bertrand ^b   Taksin, Anne Laure ^b   Gisselbrecht, Christian ^b   Jaccard, Arnaud ^b   Omuro, Antonio ^b   Sanson, Marc ^b   Janvier, Maud ^b   Kolb, Brigitte ^b   Zini, Jean Marc ^b   Leblond, Véronique ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THIOTEPA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAOCULAR TUMOR; LEUKOENCEPHALOPATHY; LYMPHOMA; MALE; MULTICENTER STUDY; NECROSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; RELAPSE; REMISSION; SALVAGE THERAPY; SEIZURE; SEPTIC SHOCK; TREATMENT FAILURE; TREATMENT RESPONSE; BRAIN TUMOR; EYE TUMOR; LARGE CELL LYMPHOMA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; EYE NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; THIOTEPA;

EID: 45149086329     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5533     Document Type: Article

References (27)

1. De Angelis L, Iwamoto FM: An update on therapy of primary central nervous system lymphoma. Hematology (Am Soc Hematol Educ Prog) 311-316, 2006
2. Jahnke K, Thiel E, Martus P, et al: Relapse of primary central nervous system lymphoma: Clinical features, outcome and prognostic factors. J Neurooncol 80:159-165, 2006
3. Nguyen PL, Chakravarti A, Finkelstein DN, et al: Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507-1513, 2005
4. Fischer L, Thiel E, Klasen HA, et al: Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62:1885-1887, 2004
5. Reni M, Mason W, Zaja F, et al: Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Hematol 40:1682-1688, 2004
6. Wong ET, Tishler R, Barron L, et al: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphoma. Cancer 101:139-145, 2004
7. Enting RH, Demopoulos A, DeAngelis LM, et al: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901-903, 2004
8. Tyson RM, Siegal T, Doolittle ND, et al: Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 44:627-633, 2003
9. Plotkin SR, Betensky RA, Hochberg FH, et al: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643-5646, 2004
10. Arellano-Rodrigo E, Lòpez-Guillermo A, Bessel EM, et al: Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (cytarabine) for patients with recurrent primary central nervous system lymphoma. Eur J Hematol 70:219-224, 2003
11. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
12. Muldoon LL, Soussain C, Jahnke K, et al: Chemotherapy delivery issues in CNS malignancy: A reality check? J Clin Oncol 25:2295-2305, 2007
13. Soussain C, Suzan F, Hoang-Xuan K, et al: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742-749, 2001
14. Abrey LE, Batchelor TT, Ferreri AJM, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005
15. Smith GA, Damon LE, Rugo HS, et al: High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833-839, 1997
16. Egorin MJ, Akman SR, Gutierrez PL: Plasma pharmacokinetics and tissue distribution of thiotepa in mice. Cancer Treat Rep 68:1265-1268, 1984
17. Heideman RL, Cole DE, Balis F, et al: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: Evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736-741, 1989
18. Vassal G, Gouyette A, Hartmann O, et al: Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24:386-390, 1989
19. Hassan M, Oberg G, Ericson K, et al: In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 30:81-85, 1992
20. O'Neill BP, Dinapoli RP, Kurtin PJ, et al: Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): How much staging is enough? J Neurooncol 25:67-71, 1995
21. Patte C, Leverger G, Perel Y, et al: Updated results of the LMB86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non-Hodgkin's lymphoma (B-NHL) with CNS involvement (CNS+) and B-ALL. Med Pediatr Oncol 18:406, 1990 (abstr)
22. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell lymphoma and leukemia in adults: A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664-674, 1995
23. Abrey LE, Moskowitz CH, Mason WP, et al: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: An intent-to-treat analysis. J Clin Oncol 21:4151-4156, 2003
24. Illerhaus G, Marks R, Ihorst G, et al: High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865-3870, 2006
25. Montemurro M, Kiefer T, Schüler F, et al: Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: Results of the multicenter Osteutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665-671, 2007
26. Colombat P, Lemevel A, Bertrand P, et al: High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38:417-420, 2006
27. Correa DD, Maron L, Harder H, et al: Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol 18:1145-1151, 2007